(Finance) – Erfo Pharmaceutical LaboratoryInnovative SMEs and benefit company operating in the nutraceutical sector, closed the exercise at 31 December 2024, with consolidated revenues of 6.2 million euros, exactly in line with respect to the same period of the previous year.
The consolidated Ebitda Adjusted at 31 December 2024 is 1.4 million (1.6 million in 2023). The slight reduction, explains the company, is mainly linked to the choice to strengthen the production and logistical structure to support international growth and new development strategies. They also impact greater marketing costs for specific initiatives concentrated in the first part of the year.
There Pfn consolidated of the period is equal to 2.1 million euros, improving compared to 1.7 million in 2023, despite the cash exit of 0.55 million euros for the payment of dividend 2023.
The pre -concground data of 2024 also bring out a Cash Conversion Rate of 100%“confirming the excellent ability of the company to generate cash with characteristic management”.
Alessandro Cutè, president and CEO of Erfo: “2024 ends with the great satisfaction of having signed the sale agreement (finalized last 14/02) for the acquisition of a majority participation of Fit & Go, leader in Italy in the High Tech Fitness sector and fast fitness. Thanks to this operation, the Erfo group projects its business on a portfolio of three different synergistic formats (Diètnatural, Bodysano and Fit & Go), which together reach over 250 points in Italy and abroad. Our first goal is on the one hand to extend nutraceutical production (also including an offer dedicated to fitness) and on the other, continue with Fit & Go the internationalization process already started with Diètnatural, which today has 5 stores in Frankophone territory with different openings envisaged in the 1st year 1st year, including one in the Paris area, which takes great importance for the whole group both from a strategic and symbolic point of view. Today we are an internationally aggregating pole in the field of nutrition, wellness and fitness, with a focus on franchising models and a strong inclination to research and technology, the main driver to expand our Medical Division. In 2024, in fact, thanks also to the research projects carried out with our scientific partners, we conducted important patent activities in the orthopedic field that will be able to produce commercial results already in 2025 “.